OREANDA-NEWS. Johnson & Johnson's booster dose of coronavirus vaccine provides fewer antibodies than Pfizer and Moderna, CNBC reported, citing a study by the US National Institutes of Health.

As noted by the TV channel, the purpose of the study was to find out the benefits and drawbacks of using various boosters. It included more than 450 participants who got booster doses of one of three vaccines which had been approved in the United States. Participants of the research were re-vaccinated either with drugs from the same company as during the first vaccination, or with medicines from a different company. Scientists counted the amount of antibodies produced two or four weeks after booster vaccinations. According to the TV channel, the study has not been reviewed yet.

The results of the study showed that all booster vaccines increased antibody levels. However, the scientists concluded that the participants who received the first vaccine with Johnson & Johnson had a better immune response with booster doses of Pfizer or Moderna.

"These data show that if a vaccine is approved or authorized as a booster, it will provide an immune response, regardless of which drug was given the first vaccine against COVID-19," the TV channel quoted the authors of the study as saying.

According to the TV channel, as a result of the study, no serious side effects or other symptoms of the disease associated with booster vaccinations were found.

Johnson & Johnson previously conducted a third round of trials of its vaccine, which showed that a booster dose administered 56 days after the first vaccination was 94% effective against mild to moderate COVID-19 and 100% effective against severe or critical disease. within at least 14 days after re-vaccination.